MOR - MorphoSys rises after Swissmedic grants temporary approval to lymphoma treatment

MorphoSys (NASDAQ:MOR) and partner Incyte (INCY) said the Swissmedic had granted temporary approval for their combination therapy, Minjuvi (tafasitamab) to treat relapsed or refractory diffuse large B-cell lymphoma. Minjuvi is given to DLBCL patinets in combination with Celgene's multiple myeloma drug lenalidomide, followed by Minjuvi monotherapy. Incyte has exclusive commercialization rights for Minjuvi in Switzerland. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S., and is marketed by Incyte under the brand name Minjuvi in Europe, the UK and Canada. Shares after market MOR +4.50%

For further details see:

MorphoSys rises after Swissmedic grants temporary approval to lymphoma treatment